FMP
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
Date
Revenue
Earnings
Estimated Earnings
Surprise
No data found!